Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > pSivida to Present at the Astrologers Fund Conference in New York City

Global drug delivery company, pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that the Company's Vice President, Investor Relations, Mr Brian Leedman, will be making a company presentation at the Astrologers Fund Conference for Emerging Hi-Growth Sectors at the Princeton Club, NYC, 1pm US EST on Tuesday, September 11th, 2007. The Company will be providing an update on the recent activities and goals moving forward.

pSivida to Present at the Astrologers Fund Conference in New York City

BOSTON & PERTH, Australia | Posted on September 10th, 2007

The Astrologers Fund Hi-Growth Sectors Conference features emerging and quality investment opportunities in attractive small, mid and microcap companies. Details about this conference can be obtained by going to the website link below:

The Company's presentation will not be webcast but can be viewed at the website link below:


About pSivida Limited
pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur™ for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. for other ophthalmic applications of the Medidur™ technology.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

pSivida’s intellectual property portfolio consists of 71 patent families, 99 granted patents, including patents accepted for issuance, and over 300 patent applications. pSivida conducts its operations from facilities near Boston in the United States, Malvern in the United Kingdom and Perth in Australia.

pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the XETRA system (PSI). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.

This release contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors that are contained in cautionary statements in the Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

pSivida Limited
Brian Leedman
Vice President, Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099

US Public Relations
Beverly Jedynak
Martin E. Janis & Company, Inc
Tel: +1 (312) 943 1123

European Public Relations
Eva Reuter
Accent Marketing Limited
Tel: +49 (254) 393 0740

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

Nanotech Grants Options September 22nd, 2016

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016


Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016

Highly conductive and pure gold nanostructures grown by electron beam induced deposition October 17th, 2016


Nanosciences: Genes on the rack October 21st, 2016

Physicists use lasers to capture first snapshots of rapid chemical bonds breaking October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

New perovskite solar cell design could outperform existing commercial technologies: Stanford, Oxford team creates high-efficiency tandem cells October 21st, 2016


Leti Scientists Participating in Sessions on Med Tech, Automotive Technologies, MEMS, Si-photonics and Lithography at SEMICON Europa: Teams also Will Demonstrate Technology Advances in Telecom, Data Fusion, Energy, Silicon Photonics and 3D Integration October 18th, 2016

The University of Applied Sciences in Upper Austria uses Deben tensile stages as an integral part of their computed tomography research and testing facility October 18th, 2016

Pokhara (Nepal) all set to host KaSAM-2016: An International Scientific Meeting on Advanced Materials October 15th, 2016

MEMS & Sensors Industry Group Reveals Tech Showcase Finalists --MSIG hosts competition for unique MEMS/sensors demos at MEMS & Sensors Executive Congress, 11/10/16 in Scottsdale, AZ October 11th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project